ArticleMicrobiology spectrum2022
Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Staphylococcus aureus biofilms: molecular mechanisms, resistance determinants, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- Monthly dalbavancin dosing for suppressive therapy: a pharmacokinetic estimation analysis and case series.Antimicrobial agents and chemotherapy · 2026Article
- The AcrAB efflux pump contributes to the virulence of EnteroaggregativeFrontiers in cellular and infection microbiology · 2025Article
- Genomic characterization and antibiotic susceptibility of biofilm-formingFrontiers in cellular and infection microbiology · 2025Article
- Article
- Vascular catheter-related infections: an endemic disease in healthcare institutions. An opinion paper of the Spanish Society of Cardiovascular Infections (SEICAV).Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience.Antibiotics (Basel, Switzerland) · 2024Article
- Biological characterization and genomic analysis of a novel methicillin-resistantMicrobiology spectrum · 2024Article
- Modulating the skin mycobiome-bacteriome and treating seborrheic dermatitis with a probiotic-enriched oily suspension.Scientific reports · 2024Article
- Efficacy of sodium hypochlorite in overcoming antimicrobial resistance and eradicating biofilms in clinical pathogens from pressure ulcers.Frontiers in microbiology · 2024Article
- Biosynthesis of Peptide Hydrogel-Titania Nanoparticle Composites with Antibacterial Properties.Gels (Basel, Switzerland) · 2023Article
- In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement.Antibiotics (Basel, Switzerland) · 2023Article
- In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Role of the MDR Efflux Pump AcrAB in Epithelial Cell Invasion byBiomolecules · 2023Article
- Preparation of Hydrogel Composites Using a Sustainable Approach for In Situ Silver Nanoparticles Formation.Materials (Basel, Switzerland) · 2023Article
- Antimicrobial Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Skin dysbiosis and Cutibacterium acnes biofilm in inflammatory acne lesions of adolescents.Scientific reports · 2022Article
- Green In Situ Synthesis of Silver Nanoparticles-Peptide Hydrogel Composites: Investigation of Their Antibacterial Activities.Gels (Basel, Switzerland) · 2022Article
- Determination of the Elution Capacity of Dalbavancin in Bone Cements: New Alternative for the Treatment of Biofilm-Related Peri-Prosthetic Joint Infections Based on anAntibiotics (Basel, Switzerland) · 2022Article
- Homocysteine and Inflammatory Cytokines in the Clinical Assessment of Infection in Venous Leg Ulcers.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has become the leading cause of skin and soft tissue infections (SSTIs). Biofilm production further complicates patient treatment, contributing to increased bacterial persistence and antibiotic tolerance. The study aimed to explore the efficacy of different antibiotics on biofilm-producing MRSA isolated from patients with SSTI. A total of 32 MRSA strains were collected from patients with SSTI. The MIC and minimal biofilm eradication concentration (MBEC) were measured in planktonic and biofilm growth. The study showed that dalbavancin, linezolid, and vancomycin all inhibited MRSA growth at their EUCAST susceptible breakpoint. Of the MRSA strains, 87.5% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.